Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Latest News

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb



USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, May 9, 2024 /PRNewswire/ — USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer Moon Shot” designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

In the case of pelareorep, an intravenously delivered immunotherapy agent developed by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), the case is getting stronger for it to one day become a treatment for multiple cancers, including most prominently pancreatic cancer. Near the end of 2022, the FDA granted pelareorep a Fast Track Designation for the treatment of pancreatic ductal adenocarcinoma (PDAC) after it demonstrated some optimistic results. Now Oncolytics is continuing to move its flagship asset forward, having recently received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRONOX +/- Tecentriq® (from Roche) in pancreatic cancer in a new cohort for its ongoing GOBLET study, following German regulatory and ethics approvals.

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.

Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC,” said Dr. Matt Coffey, President and CEO of Oncolytics. “We believe that working with PanCAN will help to further enrich Oncolytics’ clinical relationships with the pancreatic cancer community. We are also grateful for PanCAN’s Therapeutic Accelerator Award, which is enabling the evaluation of this combination therapy.”


Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep’s potential in addressing pancreatic cancer. So far, Oncolytics has already reported data for pelareorep in combination with gemcitabine and nab-paclitaxel. According to the Oncolytics team, if the mFOLFIRINOX combination shows a compelling efficacy signal, this therapeutic approach could also be advanced to a registration-enabling study, providing two opportunities for pelareorep-based treatment to benefit pancreatic cancer patients. In addition, translational research studies planned for this cohort will help to further elucidate pelareorep’s mechanism of action, including its ability to shape the tumor microenvironment (TME).

Oncolytics has taken a very strategic approach to the development of pelareorep in pancreatic cancer by focusing its clinical studies on combinations with the most widely used treatment regimens,” said Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial. “My experience to date with the GOBLET study, including the positive metastatic PDAC and encouraging anal cancer data reported last year, makes me enthusiastic to initiate enrollment in the mFOLFIRINOX cohort.”

Notably, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs) in the blood, an effect that was observed in earlier pancreatic cancer studies. According to the company, they will be initiating enrollment into the mFOLFIRINOX/pelareorep study cohort in Q2 2024.

In the case of Candel Therapeutics, Inc. (NASDAQ: CADL), another potential treatment for pancreatic cancer was given a nod by the FDA in the form of an Orphan Drug Designation given to Candel’s most advanced multimodal biological candidate, CAN-2409. The news of the designation came weeks after Candel reported updated overall survival data from its ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable PDAC.

“We recently reported data from the phase 2 randomized clinical trial of CAN-2409 in borderline resectable pancreatic cancer, showing that CAN-2409, when added to standard of care, more than doubled the median overall survival obtained with standard of care alone,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel. “We are pleased that the FDA has now granted Candel with both Orphan Drug and Fast Track Designation to this program, as we seek to reshape the treatment paradigm in pancreatic cancer.”


Pharma giant AstraZeneca PLC (NASDAQ: AZN) recently saw its revenue spike in Q1 2024, bolstered by sales of its cancer medicines, according to Bloomberg. Over the last few weeks, AstraZeneca has been making more progress across the oncology scene, including the release of topline findings from its Phase III DESTINY-Breast06 study, showing significant progression-free survival benefits in certain patients with metastatic breast cancer with its antibody-drug conjugate Enerhertu with partners Daiichi Sankyo.

As well, AstraZeneca also reported results for its CALQUENCE combination regimen, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival improvement in 1st-line mantle cell lymphoma from its ECHO Phase III trial.

“These impactful results in mantle cell lymphoma show that bringing CALQUENCE to the first-line setting significantly delays disease progression and, for the first time, shows potential to extend survival,” said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca. “The improvement in progression-free survival together with the differentiated safety profile of CALQUENCE are both important as we strive to transform outcomes earlier in the course of disease treatment.”

In combination with its Enhanze drug-delivery technology, Halozyme Therapeutics, Inc. (NASDAQ: HALO) was recently linked to the acceptance of an approval-seeking FDA application involving a subcutaneous formulation of Bristol-Myers Squibb’s blockbuster cancer drug Opdivo. As per the announcement, the application covers Opdivo co-formulated with Halozyme’s Enhanze drug-delivery technology across all previously approved adult, solid-tumor Opdivo indications as monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy or in combination with chemotherapy or cabozantinib.

Back in January, Halozyme also saw its other co-collaborator, Roche, receive European Commission approval of Tecentriq® SC with Enhanze, representing the EU’s first subcutaneous PD-(L)1 cancer immunotherapy for multiple cancer types.


“As the first subcutaneous PD-(L)1 cancer immunotherapy in Europe, Tecentriq SC can provide a new treatment option that can enhance the treatment experience for patients and caregivers while freeing up resources in constrained healthcare systems,” said Dr. Helen Torley, President and CEO of Halozyme.

Back in February, Janux Therapeutics, Inc. (NASDAQ: JANX) announced encouraging safety and efficacy data in ongoing dose escalation trials for PSMAxCD3-TRACTr JANX007 in metastatic castration-resistant prostate cancer (mCRPC) and EGFRxCD3-TRACTr JANX008 in late-stage solid tumors.

“The clinical data provide compelling proof-of-concept for the TRACTr platform in a setting where many other approaches have failed due to material safety issues or lack of efficacy,” said David Campbell, Ph.D., President and CEO, Janux Therapeutics. “Our TRACTr platform provides an entry point to multiple, large solid tumor indications that are intractable with conventional TCE approaches. We look forward to continuing to advance these clinical trials and expanding to additional TCE targets, as we look to fulfill our mission to meaningfully address the unmet medical needs for cancer patients, especially those with late-stage disease.”

The market’s immediate reaction was quite positive upon these results, but by mid-April Janux began working with an adviser after drawing interest in a potential takeover. According to Bloomberg, Janux is likely to draw interest from bigger drugmakers who are looking to acquire new medicines to replenish their portfolios or expand into cancer treatments. Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Article Source: 


[email protected]
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Banxso Celebrates Winners of the Tour de Banxso Trading Competition



CAPE TOWN, South Africa, June 13, 2024 /PRNewswire/ — Banxso, the leading online trading platform, is excited to announce the winners of its highly anticipated Tour de Banxso trading competition. After weeks of rigorous and competitive trading, the most skilled traders have emerged victorious, showcasing their expertise and dedication in the realm of online trading.

Grand Prize Winner: Rigardt Maartens from Roodepoort has been awarded the prestigious grand prize: a magnificent 1959 Mercedes-Benz 190 SL, valued at R2,800,000. In addition to this classic automobile, Rigardt also received an official Chopard® Mille Miglia® watch valued at R200,000.

Runner-Up: Helgard Gous from Brooklyn, Pretoria, has achieved a remarkable runner-up position, winning an exciting international holiday for him and his wife, and an official Chopard® Mille Miglia® watch worth R200,000.

Participants were required to make an initial deposit of R20,000 and complete at least 100 trades across a minimum of 10 different assets to be eligible for these extraordinary prizes. The winners were selected based on achieving the highest winning ratio during the competition period.

Manuel de Andrade, Banxso’s Chief Operating Officer, expressed his excitement about the competition’s success, stating, “We are thrilled by the remarkable engagement and enthusiasm displayed by our clients throughout this event. Congratulations to Rigardt and Helgard on their exceptional performance and well-deserved success.”


Rigardt Maartens shared his elation about winning the grand prize: “I am deeply honoured and grateful for this incredible reward. Competing in the Tour de Banxso has been an amazing journey, and I am proud to be a part of the Banxso community.”

Helgard Gous also conveyed his joy at being named the runner-up: “Participating in the Tour de Banxso competition has been a highly rewarding experience. I am thankful for this opportunity and look forward to continuing my trading success with Banxso.”

The winners were invited to Cape Town on Friday, June 7, to receive their prizes and meet the Banxso team before returning home.

Banxso operates under stringent regulatory oversight to ensure the highest levels of security and confidence. Authorized by the South African Financial Sector Conduct Authority (FSCA) with license number 37699, Banxso adheres to strict conditions, including the maintenance of segregated client accounts to protect client funds. Additionally, Banxso submits monthly reports to the FSCA and the Financial Intelligence Centre as part of its regulatory compliance.

Banxso offers access to CFD trading across a wide range of financial instruments, including indices, stocks, commodities, cryptocurrencies, and forex. For more information about Banxso and how to start your trading journey, please visit


About Banxso:

Based in the vibrant heart of Cape Town, Banxso is an online trading brokerage that redefines the trading experience. Banxso champions the aspirations of young traders while fostering an inclusive, dynamic, and welcoming community. As a gateway to financial trading and investing, Banxso provides an optimal platform for navigating every phase of your financial journey.

Since its inception in 2022, Banxso has operated under meticulous regulatory frameworks, ensuring security and confidence for its clients daily. Authorized by the South African Financial Sector Conduct Authority (FSCA) No. 37699, Banxso exclusively serves South African citizens.

Banxso is more than just a platform; it is your personal portal to the financial markets. Committed to empowering clients with successful and confident trading skills, Banxso has democratized the process by eliminating commissions and lowering spreads, addressing the financial realities of trading.

Recently, Banxso introduced its interest-bearing brokerage account offering up to 8.7% interest, a pioneering initiative for online traders in South Africa, with interest paid weekly in arrears.


Banxso proudly sponsors Dricus du Plessis, the current UFC Middleweight Champion and the first South African to win a UFC championship, as well as South Africa’s national soccer team, Bafana Bafana.

Media Contact:
Manpreet Singh
Email: [email protected]
Phone: +16465064978


Banxso Celebrates Winners of the Tour de Banxso Trading Competition


Cision View original content:

Continue Reading

Latest News

Frost & Sullivan Institute Announces the Fourth Edition of the Enlightened Growth Leadership Best Practices Recognition, 2024



SANTA CLARA, Calif., June 13, 2024 /PRNewswire/ — Frost & Sullivan Institute, in collaboration with Frost & Sullivan proudly announces the fourth edition of the Enlightened Growth Leadership Best Practices Recognition 2024, celebrating organizations that achieve success while making a positive global impact. In today’s rapidly changing business environment, the Institute has identified an exceptional group of multinational companies that masterfully combine business growth with sustainable transformation. These leaders are tackling pressing challenges such as reducing carbon emissions, minimizing waste, and conserving non-renewable resources, setting a new standard for responsible corporate growth.

“The Enlightened Growth Leadership Best Practices Recognition represents a dedication that goes beyond traditional corporate responsibility and governance standards. These organizations are driving transformative changes in industries and societies, steering us towards a brighter and more sustainable future. We extend our heartfelt congratulations to these exceptional companies for their steadfast commitment to sustainable development and their efforts in creating opportunities that benefit all stakeholders. Their dedication to sustainability sets a strong example for all industries,” said Aroop Zutshi, Director of the Frost & Sullivan Institute.

The selection process is underpinned by a comprehensive and robust eight-step methodology. This rigorous process involves thorough research, in-depth analyses, and benchmarking, ensuring that the selected companies truly exemplify excellence in growth and ‘innovating global challenges to zero’. By blending business expertise with ethical values, these companies show ideals that go beyond just making profits. This recognition highlights their commitment to responsible consumerism.

The Frost & Sullivan Institute proudly congratulates the Enlightened Growth Leadership Best Practices Recognition, 2024 winners from Asia Pacific. These exceptional organizations will be honored at our award banquet at Barcelona later this year, where we will celebrate their unwavering dedication to building a sustainable and prosperous future.





APL Apollo

ARE Holdings,Inc.

PT Bayan Resources, TBK



Coupang, Inc.


Data#3 Limited

Delta Electronics (Thailand) PCL.


Doosan Bobcat.

Dreamtech Co., Ltd. 


erex Co.,Ltd.

EXEO Group, Inc.



HDC Holding Co.,Ltd

Hitachi High-Tech Corporation.

Kakao Corp.




LG Chem.

M3, Inc. 

NMDC Limited.

Ramsay Health Care



Sea Limited.

Seegene Inc

SL Corporation

SRF Limited 





Airtel India.

Bharat Petroleum Corporation Limited


Hindustan Petroleum Corporation Limited

Idemitsu Kosan Co.,Ltd.


PHC Holdings Corporation

PTT Public Company Limited


Toyota Tsusho Corporation


About Frost & Sullivan Institute

The Frost & Sullivan Institute (FSI) is a non-profit organization dedicated to utilizing business practices to address global priorities. The genesis of the institute goes back to the vision of either creating, or becoming part of, a solution that addresses threats to humanity. The Institute has identified strategic imperatives for transformation and believes that we can truly accelerate innovation to zero. To learn more about FSI, visit

About Frost & Sullivan


For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Media Contact:

Bivechana Gautam
Email: [email protected] 

Related Links

Photo –


Cision View original content:–sullivan-institute-announces-the-fourth-edition-of-the-enlightened-growth-leadership-best-practices-recognition-2024-302171873.html

Continue Reading

Latest News

JanOne’s Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024



LAS VEGAS, June 13, 2024 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, released today its wholly-owned subsidiary, ALT5 Sigma, transaction volume for April and May 2024.

According to the Company, ALT5 Sigma transaction volume reached US$289 million for the months of April and May 2024 combined, compared to US$151 million in transaction volume for the months of April and May 2023 combined, representing a year-over-year increase of 91%.

“Since inception, we have relied solely on word-of-mouth and client referrals to grow our business and have managed a steady growth year-over-year, and now we begin to roll out our global marketing strategies,” said Andre Beauchesne, President of Alt5 Sigma. “The adoption of cryptocurrencies in many industries is accelerating and our B2B solutions can be easily integrated into all business processes from checkout to payouts,” further added Mr. Beauchesne.

About ALT5 Sigma Inc.

Launched in 2018, ALT5 is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5, through its subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime”. The Company processed over US$1.2 billion in cryptocurrency transactions in 2023.


ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

About JanOne

JanOne is a unique Nasdaq-listed multidisciplinary organization with a focus on healthcare and fintech. JanOne is one of the constituents of the Russell Microcap Index, starting June 28, 2024. Through its biotech activities, JanOne is developing innovative, actionable solutions intended to help end the opioid crisis. JanOne is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation’s history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.

JanOne’s ALT5 subsidiary is a global fintech that provides next generation blockchain powered technologies for the trading, clearing, settlement, payment, and custodianship of digital instruments.


Please visit for additional information.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the statements that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential”, and other similar expressions. This press release also contains statements and links relating to the profitability and prospective growth of ALT5’s platforms and business, including, but not limited to international currency risks, third-party or customer credit risks, liability claims stemming from Alt5’s services, and technology challenges for future growth or expansion. Such statements reflect JanOne’s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by JanOne, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies.

Many factors could cause JanOne’s actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in JanOne’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and JanOne does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. JanOne cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media Contact Investor Relations
[email protected]


Logo –

Cision View original content:

Continue Reading